JP2011505371A - 抗−ｒｇ−１抗体の複合体 - Google Patents

抗−ｒｇ−１抗体の複合体 Download PDF

Info

Publication number
JP2011505371A
JP2011505371A JP2010536173A JP2010536173A JP2011505371A JP 2011505371 A JP2011505371 A JP 2011505371A JP 2010536173 A JP2010536173 A JP 2010536173A JP 2010536173 A JP2010536173 A JP 2010536173A JP 2011505371 A JP2011505371 A JP 2011505371A
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010536173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505371A5 (enExample
Inventor
デイビッド・ジェイ・キング
ジョナサン・エイ・テレット
サンジーブ・ギャングウォー
ジョセフィーン・エム・カーダレリ
チェタナ・ラオ−ナイク
チン・パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40427118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011505371(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2011505371A publication Critical patent/JP2011505371A/ja
Publication of JP2011505371A5 publication Critical patent/JP2011505371A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2010536173A 2007-11-30 2008-11-26 抗−ｒｇ−１抗体の複合体 Withdrawn JP2011505371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99169007P 2007-11-30 2007-11-30
PCT/US2008/084899 WO2009073524A2 (en) 2007-11-30 2008-11-26 Conjugates of anti-rg-1 antibodies

Publications (2)

Publication Number Publication Date
JP2011505371A true JP2011505371A (ja) 2011-02-24
JP2011505371A5 JP2011505371A5 (enExample) 2011-11-04

Family

ID=40427118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536173A Withdrawn JP2011505371A (ja) 2007-11-30 2008-11-26 抗−ｒｇ−１抗体の複合体

Country Status (18)

Country Link
US (1) US20110020329A1 (enExample)
EP (1) EP2211908A2 (enExample)
JP (1) JP2011505371A (enExample)
KR (1) KR20100101122A (enExample)
CN (1) CN101951960A (enExample)
AR (1) AR069746A1 (enExample)
AU (1) AU2008331507A1 (enExample)
BR (1) BRPI0819765A2 (enExample)
CA (1) CA2707443A1 (enExample)
CL (1) CL2008003525A1 (enExample)
CO (1) CO6210734A2 (enExample)
EA (1) EA201000921A1 (enExample)
IL (1) IL206060A0 (enExample)
MX (1) MX2010005683A (enExample)
NZ (1) NZ586514A (enExample)
TW (1) TW200930407A (enExample)
WO (1) WO2009073524A2 (enExample)
ZA (1) ZA201003729B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010374B1 (ru) * 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) * 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
EP3092010B1 (en) 2014-01-10 2018-07-11 Synthon Biopharmaceuticals B.V. Method for purifying cys-linked antibody-drug conjugates
EP3661966A4 (en) * 2017-07-31 2021-07-21 Tizona Therapeutics ANTI-CD39 ANTIBODIES, COMPOSITIONS INCLUDING ANTI-CD39 ANTIBODIES AND METHODS OF USE OF ANTI-CD39 ANTIBODIES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912227A (en) * 1984-02-21 1990-03-27 The Upjohn Company 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds
US4978757A (en) * 1984-02-21 1990-12-18 The Upjohn Company 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds
US5332837A (en) * 1986-12-19 1994-07-26 The Upjohn Company CC-1065 analogs
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
WO1991016324A1 (en) * 1990-04-25 1991-10-31 The Upjohn Company Novel cc-1065 analogs
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE271557T1 (de) * 1994-04-22 2004-08-15 Kyowa Hakko Kogyo Kk Dc-89 derivat
JPH07309761A (ja) * 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US6989452B2 (en) * 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US7091186B2 (en) * 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
MXPA06000798A (es) * 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
MXPA06013413A (es) * 2004-05-19 2007-01-23 Medarex Inc Enlazadores quimicos y conjugados de los mismos.
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
JP5290756B2 (ja) * 2005-09-26 2013-09-18 メダレックス インコーポレイテッド 抗体−薬剤コンジュゲート及びその使用
WO2007059404A2 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2799449A1 (en) * 2006-05-25 2014-11-05 Bayer Intellectual Property GmbH Dimeric molecular complexes

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517842A (ja) * 2011-05-26 2014-07-24 ブリストル−マイヤーズ スクイブ カンパニー 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017128571A (ja) * 2011-05-26 2017-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫コンジュゲート、それらを含有する組成物、ならびに製造方法および使用方法
JP2017510548A (ja) * 2014-01-29 2017-04-13 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途

Also Published As

Publication number Publication date
WO2009073524A2 (en) 2009-06-11
NZ586514A (en) 2012-05-25
AR069746A1 (es) 2010-02-17
EA201000921A1 (ru) 2010-12-30
US20110020329A1 (en) 2011-01-27
ZA201003729B (en) 2011-08-31
CN101951960A (zh) 2011-01-19
IL206060A0 (en) 2010-11-30
KR20100101122A (ko) 2010-09-16
MX2010005683A (es) 2010-06-11
AU2008331507A1 (en) 2009-06-11
CO6210734A2 (es) 2010-10-20
CL2008003525A1 (es) 2010-01-22
TW200930407A (en) 2009-07-16
BRPI0819765A2 (pt) 2015-05-05
EP2211908A2 (en) 2010-08-04
CA2707443A1 (en) 2009-06-11
WO2009073524A3 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
US8865875B2 (en) Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8399623B2 (en) Human antibodies that bind mesothelin, and uses thereof
US20120027782A1 (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
US8481683B2 (en) Human antibodies that bind CD22 and uses thereof
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20100150950A1 (en) Human antibodies that bind cd70 and uses thereof
US20100104509A1 (en) Human antibodies that bind cd19 and uses thereof
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
US20110020329A1 (en) Conjugates of anti-rg-1 antibodies
HK1140943B (en) Human antibodies that bind mesothelin, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110913

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121017